Novo Nordisk and other members of the Diabetes Advocacy Alliance™ (DAA) have successfully advocated in the past few years for federal funds to support diabetes prevention; however, the fight for adequate resources continues.
The Affordable Care Act (ACA) authorized the creation of the National Diabetes Prevention Program (National DPP) at the Centers for Disease Control and Prevention (CDC). According to the CDC, the National DPP is “an evidence-based lifestyle change program for preventing type 2 diabetes.”1
Novo Nordisk advocates for funding for the National DPP and supports legislation to make diabetes prevention a covered benefit for seniors in Medicare. You can express support for the National DPP to your members of Congress through Novo Nordisk’s Act for Diabetes website.
In the past, Novo Nordisk supported prevention of type 2 diabetes by serving as a co-chair of the Medicare Diabetes Screening Project and providing grants to the YMCA of the USA for pilot projects designed to learn more about reaching and recruiting adults in Medicare aged 65 and older into local National DPP programs.
To learn more about where programs are underway across the nation, visit the Centers for Disease Control and Prevention's (CDC) website.
© 2016 Novo Nordisk All rights reserved. 0415-00026489-1 January 2016